Skip to content
Search AI Powered

Latest Stories

What’s Going on with New York’s Legal Cannabis Roll Out? 

What's Going on With New York's Legal Cannabis Rollout
What's Going on With New York's Legal Cannabis Rollout

The New York cannabis industry is facing a complex and challenging landscape as it transitions from a medical marijuana program to a fully legal recreational market. Despite the recent legalization of adult-use cannabis in the state, there are still many issues to be addressed, including regulatory compliance, licensing, distribution, capital and equity concerns, and of course, litigation.

Recently, several lawsuits have been filed against the New York State Cannabis Control Board (CCB) and the Office of Cannabis Management (OCM), which are the agencies responsible for overseeing the state's cannabis industry.


One of the lawsuits filed in late in 2022, was brought forth by Variscite, a company registered under the laws of New York, which applied for a CAURD (Cannabis Control Board Adult-Use Retail Dispensary) license. At issue is the fact that the majority owner of Variscite had a cannabis conviction under Michigan law and no significant connection to New York, Variscite was deemed ineligible for the license. 

Variscite argued in its lawsuit that the New York residency requirement was discriminatory against out-of-state applicants and violated the Dormant Commerce Clause (DCC) implied in the Constitution. A federal judge agreed with Variscite's argument and ruled that the residency requirement did not serve a compelling state policy and, therefore, violated the DCC. During the application process, Variscite selected Brooklyn, Central New York, the Finger Lakes, the Mid-Hudson area, and Western New York as possible regions for licensure. 

Consequently, the judge ruled that New York could not issue CAURD licenses for dispensaries in those regions while the case was pending. This decision is expected to affect around 63 of the 150 CAURD licenses that the Office of Cannabis Management had planned to issue by the end of 2022. However, the ruling did not affect eleven other regions, including the Bronx, Manhattan, Queens, Staten Island, and Long Island.

Another lawsuit was recently filed by a group of larger cannabis companies, including Acreage Holdings, Columbia Care, and Curaleaf and a group of medical cannabis professionals and patients has filed a lawsuit against the state of New York, claiming that the recently passed recreational cannabis law infringes on their right to affordable and accessible medicine. The lawsuit argues that the new law, which allows for the establishment of a recreational cannabis market, will lead to shortages and increased prices for medical cannabis products. The plaintiffs contend that the state is obligated to ensure a steady supply of affordable medical cannabis products for patients, and that the new law fails to meet that obligation. 

The case highlights the challenges of balancing the needs of medical cannabis patients with the desire to establish a thriving recreational market, as more states move to legalize cannabis for both medical and recreational use.

The lawsuits come at a time when the state is still developing and finalizing its regulations for the new adult-use cannabis market. The OCM recently released its proposed rules for the industry, which include provisions aimed at promoting social equity and ensuring that small businesses have a fair shot at participating in the market.

Despite all these efforts, many stakeholders in the cannabis industry are concerned about the potential for large, out-of-state operators to dominate the market and squeeze out smaller, less capitalized local upstart businesses before they get a chance to get off the ground. They are also worried about the potential for regulatory overreach and heavy-handed enforcement.

As the state moves forward with the implementation of its new recreational cannabis market, it will need to address these and a host of other concerns in order to create a fair and equitable industry that benefits all stakeholders, from large corporations to small businesses and individual consumers. 

The lawsuits filed against the CCB and OCM are just one indication of the complex and challenging landscape that lies ahead for New York's nascent legal cannabis industry.

And, the response from across the New York cannabis industry has been mixed. Some industry leaders argue that the lawsuits are misguided and that the new laws will ultimately benefit medical cannabis patients by increasing overall demand for cannabis products and driving down prices. Others, however, acknowledge that there may be some short-term disruptions as the recreational market ramps up, and they urge the state government to take steps to ensure that medical cannabis patients are not unduly affected.

Overall, the lawsuits highlight the complex and sometimes competing interests at play in the expanding cannabis industry, as well as the challenges of balancing the needs of medical cannabis patients with the desire to establish a thriving recreational market and those interested in building an equitable and fair industry for those communities most directly impacted by the war on drugs. 

As more states legalize cannabis for both medical and recreational use, similar issues are likely to arise, and policymakers will need to not only carefully consider the impact of their decisions on all stakeholders involved, but to actually invest the time and resources in listening to each of these stakeholders and involving them in decision making process. 

Overall, the development of NY’s nascent cannbis market to a mature cannabis market is going to be a complex and dynamic process that will require careful attention to changing market conditions, industry, consumer and patient needs and regulatory requirements. 

We have to remember that we are still in the first inning of this and we will see NY’s legal cannabis industry thriving in the coming months, lawsuits and all. We’re NYers after all and we don’t let much, if anything, stand in our way. 

As Alicia Keys so soulfully sings: 

Even if it ain't all it seems

We got a pocketful of dreams 

Baby, we’re from New York

Concrete jungle where dreams are made of

There's nothin' we can't do

Now, we’re in New York

These streets will make us feel brand-new

Now, let’s hear it for New York, New York, New York

More For You

Comprehensive Glossary of Cannabis Terminology - The Bluntness
Cannabis Terminology - The Bluntness
Photo by Margo Amala on Unsplash

Are You Ready to Master Cannabis Lingo? Explore Essential Terms Now

This glossary covers key cannabis-related terms that can help consumers better understand the cannabis industry, products, and their effects. Whether you're new to cannabis or looking to deepen your knowledge, these definitions offer clarity on common terms you might encounter.

Cannabis Basics: What is Cannabis?

Cannabis is a fascinating plant species that includes three main types: Cannabis sativa, Cannabis indica, and Cannabis ruderalis. Each of these species has unique characteristics and effects. The cannabis plant is a complex organism, rich in various compounds such as cannabinoids, terpenes, and flavonoids. These compounds contribute to the plant’s diverse range of effects and therapeutic benefits. Cannabis plants are cultivated for both medicinal and recreational purposes, and they can be consumed in multiple forms, including dried flower, extracts, and edibles. Whether you’re interested in the energizing effects of Cannabis sativa, the relaxing properties of Cannabis indica, or the unique traits of Cannabis ruderalis, there’s a cannabis plant to suit every need.

Cannabis Products: Cannabis Extracts

Cannabis extracts are highly potent products derived from the cannabis plant using various extraction methods, such as solvents or CO2. These extracts are concentrated forms of cannabis that can be used in several ways, including dabbing, vaporizing, or as ingredients in edibles and topicals. There are several types of cannabis extracts, each with its own texture and potency, including wax, shatter, oil, and crumble. These products are often favored for their high cannabinoid content and are commonly used for medicinal purposes, such as pain relief and anxiety management. Whether you’re looking for a powerful dabbing experience or a potent ingredient for your homemade edibles, cannabis extracts offer a versatile and effective option.

Keep ReadingShow less
Kanye West Is Spiraling—And Our Mental Health System Is Letting It Happen - The Bluntness
Kanye West Is Spiraling—And Our Mental Health System Is Letting It Happen - The Bluntness
Photo by Axel Antas-Bergkvist on Unsplash

Kanye West Is Spiraling—And Our Mental Health System Is Letting It Happen - The Bluntness

Kanye West, aka Ye, isn’t just trending—he’s unraveling in real time. And instead of intervention, we get viral clips, condemnation, and an audience watching a man self-destruct. His latest stunt? Airing a Super Bowl ad promoting a swastika-emblazoned Yeezy shirt on his site—a move so blatantly antisemitic that even the most die-hard supporters had to step back. This act garnered significant media coverage, leading to brands cutting ties and agents dropping him. His social media account faced scrutiny and was ultimately deleted after a history of controversial postings. But here’s the problem: canceling Kanye doesn’t fix Kanye.

At this point, the question isn’t whether his actions are inexcusable (they are). The question is, what happens when one of the world’s most influential figures is also one of the most untreated cases of mental illness in pop culture history?

Keep ReadingShow less
Image of the famous Welcome to Fabulous Las Vegas Nevada sign in Las Vegas, NV
Nevada’s First Cannabis Lounge Closes—And It’s a Symptom of a Bigger Problem
Photo by David Vives on Unsplash

Nevada’s First Cannabis Lounge Closes—And It’s a Symptom of a Bigger Problem

Tags: Cannabis Lounges, Nevada, Cannabis Policy, Legalization, Industry Reform, Small Business

When Smoke and Mirrors, Nevada’s first state-licensed cannabis consumption lounge, opened in early 2024, it was hailed as a major milestone for the state’s adult-use market and a potential blueprint for others across the country. Less than a year later, it's permanently closed.

Keep ReadingShow less
map of medical and recreational cannabis retailers in state of New York
NY Cannabis Program Under Fire for Misconduct
NY Cannabis Program Under Fire for Misconduct

Legal Weed, Legit?

New York’s legal cannabis industry was supposed to be the nation’s model of equity and regulation. Instead, it’s quickly becoming a cautionary tale. And the latest news doesn’t just raise eyebrows—it should set off alarms across the entire industry.

According to an April 7 report byThe New York Times, New York State regulators are conducting a sweeping investigation into some of the biggest cannabis companies operating in the state—Stiiizy, Grön, Mfused, and others—over allegations of using out-of-state or unauthorized cannabis to produce products for legal dispensaries. It’s a practice insiders call inversion—and it’s been the industry’s not-so-secret open secret for years.

Keep ReadingShow less
image of California coast, pacific coast highway at sunset
How Overregulation Crushed California’s Gold Flora—And Why Other States Should Be Worried
Photo by Matthew Hamilton on Unsplash

Overregulation Kills Gold Flora

When California-based Gold Flora entered the legal cannabis scene, the company was poised to dominate. Backed by serious money and a sprawling, vertically integrated operation—from a 100,000-square-foot cultivation campus in the desert to marquee dispensaries in West Hollywood and San Jose—Gold Flora wasn't just riding the green wave. It was supposed to be the wave.

But by the end of March 2025, the company had filed for receivership, its assets now headed to auction. And while headlines cite "merger woes" and "market conditions," the real culprit behind Gold Flora’s collapse is far more systemic: a regulatory stranglehold that has quietly choked the life out of California’s once-promising cannabis economy.

Keep ReadingShow less